Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch

James M. Haughian, Mauricio P. Pinto, J. Chuck Harrell, Brian S. Bliesner, Kristiina M. Joensuu, Wendy W. Dye, Carol A. Sartorius, Aik-Choon Tan, Païvi Heikkilä, Charles M. Perou, Kathryn B. Horwitz

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Luminal breast cancers express estrogen (ER) and/or progesterone (PR) receptors and respond to hormone therapies. Basal-like "triple negative" cancers lack steroid receptors but are cytokeratin (CK) 5- positive and require chemotherapy. Here we show that more than half of primary ER +PR + breast cancers contain an ER -PR -CK5 +"luminobasal" subpopulation exceeding 1% of cells. Starting from ER +PR + luminal cell lines, we generated lines with varying luminal to luminobasal cell ratios and studied their molecular and biological properties. In luminal disease, luminobasal cells expand in response to antiestrogen or estrogen withdrawal therapies. The phenotype and gene signature of the hormone-resistant cells matches that of clinical triple negative basal-like and claudin-low disease. Luminobasal cell expansion in response to hormone therapies is regulated by Notch1 signaling and can be blocked by γ-secretase inhibitors. Our data establish a previously unrecognized plasticity of ER +PR + luminal breast cancers that, without genetic manipulation, mobilizes outgrowth of hormone-resistant basal-like disease in response to treatment. This undesirable outcome can be prevented by combining endocrine therapies with Notch inhibition.

Original languageEnglish
Pages (from-to)2742-2747
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number8
DOIs
Publication statusPublished - 2012 Feb 21
Externally publishedYes

Fingerprint

Estrogens
Maintenance
Hormones
Progesterone
Breast Neoplasms
Keratin-5
Therapeutics
Amyloid Precursor Protein Secretases
Estrogen Receptor Modulators
Steroid Receptors
Progesterone Receptors
Estrogen Receptors
Phenotype
Drug Therapy
Cell Line
Genes
Neoplasms

Keywords

  • Basal breast cancer
  • Endocrine therapy
  • Estrogen receptor
  • Slug

ASJC Scopus subject areas

  • General

Cite this

Haughian, J. M., Pinto, M. P., Harrell, J. C., Bliesner, B. S., Joensuu, K. M., Dye, W. W., ... Horwitz, K. B. (2012). Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proceedings of the National Academy of Sciences of the United States of America, 109(8), 2742-2747. https://doi.org/10.1073/pnas.1106509108

Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. / Haughian, James M.; Pinto, Mauricio P.; Harrell, J. Chuck; Bliesner, Brian S.; Joensuu, Kristiina M.; Dye, Wendy W.; Sartorius, Carol A.; Tan, Aik-Choon; Heikkilä, Païvi; Perou, Charles M.; Horwitz, Kathryn B.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 8, 21.02.2012, p. 2742-2747.

Research output: Contribution to journalArticle

Haughian, JM, Pinto, MP, Harrell, JC, Bliesner, BS, Joensuu, KM, Dye, WW, Sartorius, CA, Tan, A-C, Heikkilä, P, Perou, CM & Horwitz, KB 2012, 'Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch', Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 8, pp. 2742-2747. https://doi.org/10.1073/pnas.1106509108
Haughian, James M. ; Pinto, Mauricio P. ; Harrell, J. Chuck ; Bliesner, Brian S. ; Joensuu, Kristiina M. ; Dye, Wendy W. ; Sartorius, Carol A. ; Tan, Aik-Choon ; Heikkilä, Païvi ; Perou, Charles M. ; Horwitz, Kathryn B. / Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. In: Proceedings of the National Academy of Sciences of the United States of America. 2012 ; Vol. 109, No. 8. pp. 2742-2747.
@article{9af5a0fc32684240adf06a6b1e46fccc,
title = "Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch",
abstract = "Luminal breast cancers express estrogen (ER) and/or progesterone (PR) receptors and respond to hormone therapies. Basal-like {"}triple negative{"} cancers lack steroid receptors but are cytokeratin (CK) 5- positive and require chemotherapy. Here we show that more than half of primary ER +PR + breast cancers contain an ER -PR -CK5 +{"}luminobasal{"} subpopulation exceeding 1{\%} of cells. Starting from ER +PR + luminal cell lines, we generated lines with varying luminal to luminobasal cell ratios and studied their molecular and biological properties. In luminal disease, luminobasal cells expand in response to antiestrogen or estrogen withdrawal therapies. The phenotype and gene signature of the hormone-resistant cells matches that of clinical triple negative basal-like and claudin-low disease. Luminobasal cell expansion in response to hormone therapies is regulated by Notch1 signaling and can be blocked by γ-secretase inhibitors. Our data establish a previously unrecognized plasticity of ER +PR + luminal breast cancers that, without genetic manipulation, mobilizes outgrowth of hormone-resistant basal-like disease in response to treatment. This undesirable outcome can be prevented by combining endocrine therapies with Notch inhibition.",
keywords = "Basal breast cancer, Endocrine therapy, Estrogen receptor, Slug",
author = "Haughian, {James M.} and Pinto, {Mauricio P.} and Harrell, {J. Chuck} and Bliesner, {Brian S.} and Joensuu, {Kristiina M.} and Dye, {Wendy W.} and Sartorius, {Carol A.} and Aik-Choon Tan and Pa{\"i}vi Heikkil{\"a} and Perou, {Charles M.} and Horwitz, {Kathryn B.}",
year = "2012",
month = "2",
day = "21",
doi = "10.1073/pnas.1106509108",
language = "English",
volume = "109",
pages = "2742--2747",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch

AU - Haughian, James M.

AU - Pinto, Mauricio P.

AU - Harrell, J. Chuck

AU - Bliesner, Brian S.

AU - Joensuu, Kristiina M.

AU - Dye, Wendy W.

AU - Sartorius, Carol A.

AU - Tan, Aik-Choon

AU - Heikkilä, Païvi

AU - Perou, Charles M.

AU - Horwitz, Kathryn B.

PY - 2012/2/21

Y1 - 2012/2/21

N2 - Luminal breast cancers express estrogen (ER) and/or progesterone (PR) receptors and respond to hormone therapies. Basal-like "triple negative" cancers lack steroid receptors but are cytokeratin (CK) 5- positive and require chemotherapy. Here we show that more than half of primary ER +PR + breast cancers contain an ER -PR -CK5 +"luminobasal" subpopulation exceeding 1% of cells. Starting from ER +PR + luminal cell lines, we generated lines with varying luminal to luminobasal cell ratios and studied their molecular and biological properties. In luminal disease, luminobasal cells expand in response to antiestrogen or estrogen withdrawal therapies. The phenotype and gene signature of the hormone-resistant cells matches that of clinical triple negative basal-like and claudin-low disease. Luminobasal cell expansion in response to hormone therapies is regulated by Notch1 signaling and can be blocked by γ-secretase inhibitors. Our data establish a previously unrecognized plasticity of ER +PR + luminal breast cancers that, without genetic manipulation, mobilizes outgrowth of hormone-resistant basal-like disease in response to treatment. This undesirable outcome can be prevented by combining endocrine therapies with Notch inhibition.

AB - Luminal breast cancers express estrogen (ER) and/or progesterone (PR) receptors and respond to hormone therapies. Basal-like "triple negative" cancers lack steroid receptors but are cytokeratin (CK) 5- positive and require chemotherapy. Here we show that more than half of primary ER +PR + breast cancers contain an ER -PR -CK5 +"luminobasal" subpopulation exceeding 1% of cells. Starting from ER +PR + luminal cell lines, we generated lines with varying luminal to luminobasal cell ratios and studied their molecular and biological properties. In luminal disease, luminobasal cells expand in response to antiestrogen or estrogen withdrawal therapies. The phenotype and gene signature of the hormone-resistant cells matches that of clinical triple negative basal-like and claudin-low disease. Luminobasal cell expansion in response to hormone therapies is regulated by Notch1 signaling and can be blocked by γ-secretase inhibitors. Our data establish a previously unrecognized plasticity of ER +PR + luminal breast cancers that, without genetic manipulation, mobilizes outgrowth of hormone-resistant basal-like disease in response to treatment. This undesirable outcome can be prevented by combining endocrine therapies with Notch inhibition.

KW - Basal breast cancer

KW - Endocrine therapy

KW - Estrogen receptor

KW - Slug

UR - http://www.scopus.com/inward/record.url?scp=84857398226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857398226&partnerID=8YFLogxK

U2 - 10.1073/pnas.1106509108

DO - 10.1073/pnas.1106509108

M3 - Article

C2 - 21969591

AN - SCOPUS:84857398226

VL - 109

SP - 2742

EP - 2747

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -